So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after ...

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...

Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications.

The stock has climbed in the double-digits in recent years. Vertex Pharmaceuticals ( VRTX 1.53%) has proven itself to be an ...

With a volume of 1,752,912, the price of VRTX is up 1.48% at $439.58. RSI indicators hint that the underlying stock may be ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

A lot can change in five years. Take Vertex Pharmaceuticals (NASDAQ: VRTX), for example. In late 2020, the big biotech ...

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll ...

Vertex Pharmaceuticals' core business is still firing on all cylinders. The biotech is expanding into other areas and diversifying its portfolio. Shares of Vertex look too attractive to pass up right ...